Sulindac
Sulindac is a non-steroidal anti-inflammatory drug (NSAID) that inhibits COX-1 and COX-2. Sulindac exhibits anti-inflammatory, tocolytic, neuroprotective, anti-metastatic, and anticancer chemotherapeutic activities. In vitro, sulindac inhibits phosphodiesterases (PDEs), increasing levels of cGMP and activation of PKG and inhibiting expression of β-catenin. In animal models of ischemic stroke, sulindac decreases infarct size and increases expression of Akt, Bcl-2, and HSP 27. This compound inhibits invasion of breast cancer cells and colon cancer cells by decreasing NF-κB-mediated transcription of several miRNAs. Additionally, sulindac downregulates expression of STAT3 and survivin and decreases cell proliferation and tumor growth in cellular and animal models of laryngeal cancer.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18974178
| Cas No. |
38194-50-2 |
|---|---|
| Purity |
≥98% |
| Formula |
C20H17FO3S |
| Formula Wt. |
356.42 |
| Chemical Name |
(Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl) phenyl)methylene)-1H-indene-3-acetic acid |
| IUPAC Name |
2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid |
| Synonym |
Arthrocine; Sulindac sulfoxide; Clinoril; Clisundac; Reumofil |
| Melting Point |
183°C |
| Solubility |
Soluble in DMSO (100 mM) or ethanol (25 mM). |
| Appearance |
Yellow crystalline powder, odorless |
Modi JP, Gharibani PM, Ma Z, et al. Protective mechanism of sulindac in an animal model of ischemic stroke. Brain Res. 2014 Aug 12;1576:91-9. PMID: 24968090.
Li N, Xi Y, Tinsley HN, et al. Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling. Mol Cancer Ther. 2013 Sep;12(9):1848-59. PMID: 23804703.
Li X, Gao L, Cui Q, et al. Sulindac inhibits tumor cell invasion by suppressing NF-κB-mediated transcription of microRNAs. Oncogene. 2012 Nov 29;31(48):4979-86. PMID: 22286762.
Scheper MA, Nikitakis NG, Chaisuparat R, et al. Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma. Neoplasia. 2007 Mar;9(3):192-9. PMID: 17401459.
